microRNA-155 Is Decreased During Atherosclerosis Regression and Is Increased in Urinary Extracellular Vesicles During

Stephen Fitzsimons1, Silvia Oggero2, Robyn Bruen1

  • 1Diabetes Complications Research Centre, School of Biomolecular and Biomedical Science, Conway Institute, University College Dublin, Dublin, Ireland.

Frontiers in Immunology
|January 4, 2021
PubMed
Abstract

Insights

Conjugated linoleic acid (CLA) reduces atherosclerosis by decreasing miR-155 expression, a microRNA that suppresses anti-inflammatory signaling. Increased miR-155 in urinary extracellular vesicles (uEVs) may indicate unstable coronary artery disease (CAD).

Area of Science:

  • Cardiovascular Research
  • Molecular Biology
  • Inflammation and Immunology

Background:

  • Atherosclerosis is a chronic inflammatory disease involving macrophage accumulation in arteries.
  • MicroRNAs (miRNAs) regulate macrophage polarization and inflammation, impacting inflammatory protein expression and cholesterol transport.
  • Conjugated linoleic acid (CLA), a pro-resolving mediator, has shown potential in inducing atherosclerosis regression.

Purpose of the Study:

  • To investigate the effect of CLA on miR-155-5p (miR-155) expression during atherosclerosis regression.
  • To explore the role of miR-155 in macrophage inflammation and its potential as a biomarker in coronary artery disease (CAD).
  • To analyze alterations in urinary-derived extracellular vesicles (uEVs) and their miRNA content in patients with varying CAD stability.

Main Methods:

  • Quantified miR-155 expression in mouse aortae and human THP-1 macrophages treated with CLA.
  • Utilized a miR-155 mimic to assess its inflammatory effects on macrophages and human carotid endarterectomy (CEA) plaque specimens.
  • Analyzed surface marker expression and miR content in uEVs from patients with stable and unstable CAD.

Main Results:

  • CLA supplementation decreased miR-155 expression in aorta during atherosclerosis regression in vivo and in vitro.
  • miR-155 mimic reduced anti-inflammatory signaling proteins (BCL-6, p-STAT-3) in macrophages and downregulated BCL-6 in CEA plaques.
  • Patients with unstable CAD exhibited increased miR-155 in uEVs, alongside altered uEV surface marker expression (increased CD45+, CD11b+; decreased CD16+).

Conclusions:

  • miR-155 suppresses anti-inflammatory signaling in macrophages and is downregulated during atherosclerosis regression.
  • Increased miR-155 in uEVs from unstable CAD patients suggests its potential as a prognostic biomarker.
  • miR-155 represents a potential therapeutic target for atherosclerosis and related inflammatory conditions.